Viewray Inc (NASDAQ:VRAY) has been assigned an average rating of “Buy” from the twelve research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $12.63.
Several research analysts have recently commented on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $13.00 target price on shares of Viewray in a report on Thursday, December 6th. ValuEngine raised Viewray from a “hold” rating to a “buy” rating in a report on Wednesday, January 16th. Zacks Investment Research raised Viewray from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a report on Saturday, February 9th. BidaskClub raised Viewray from a “sell” rating to a “hold” rating in a report on Tuesday, January 1st. Finally, B. Riley reaffirmed a “buy” rating and set a $12.00 price objective (down previously from $13.75) on shares of Viewray in a report on Monday, March 11th.
Shares of VRAY opened at $8.17 on Friday. The company has a market capitalization of $782.11 million, a PE ratio of -7.86 and a beta of 1.30. The company has a debt-to-equity ratio of 0.25, a quick ratio of 5.56 and a current ratio of 6.47. Viewray has a one year low of $4.86 and a one year high of $13.21.
Viewray (NASDAQ:VRAY) last announced its earnings results on Thursday, March 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $20.66 million for the quarter, compared to the consensus estimate of $20.38 million. Viewray had a negative return on equity of 105.63% and a negative net margin of 105.09%. Viewray’s revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.38) EPS. On average, sell-side analysts expect that Viewray will post -0.91 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of VRAY. Geode Capital Management LLC lifted its stake in shares of Viewray by 12.7% in the 4th quarter. Geode Capital Management LLC now owns 662,946 shares of the company’s stock valued at $4,024,000 after purchasing an additional 74,630 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Viewray in the 4th quarter valued at $420,000. FMR LLC lifted its stake in shares of Viewray by 2.8% in the 4th quarter. FMR LLC now owns 9,561,726 shares of the company’s stock valued at $58,039,000 after purchasing an additional 256,939 shares during the period. Penn Capital Management Co. Inc. lifted its stake in shares of Viewray by 123.6% in the 4th quarter. Penn Capital Management Co. Inc. now owns 523,565 shares of the company’s stock valued at $3,178,000 after purchasing an additional 289,449 shares during the period. Finally, Advisory Services Network LLC acquired a new position in shares of Viewray in the 4th quarter valued at $56,000.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Featured Story: Why are percentage gainers important?
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.